Literature DB >> 17197896

Occurrence of endometrial glandular dysplasia precedes uterine papillary serous carcinoma.

Wenxin Zheng1, Sharon X Liang, Xiaofang Yi, E Cagnur Ulukus, John R Davis, Setsuko K Chambers.   

Abstract

Endometrial glandular dysplasia (EmGD) is a newly defined entity that is commonly and specifically associated with serous endometrial intraepithelial carcinoma and uterine papillary serous carcinoma (UPSC). Endometrial glandular dysplasia has been proposed as a true precancerous lesion of UPSC based on our recent studies showing morphological and molecular linkages between these 2 lesions. The present report is to examine if EmGD occurs before UPSC development and to define the period from the occurrence of EmGD to a full-blown UPSC by studying their clinicopathologic features in a retrospective setting. A total of 250 UPSC and 258 benign cases were used as initial study source. To identify if EmGD existed before the development of UPSC, we blindly reviewed all available endometrial biopsies from a period of 3 months or earlier before hysterectomies. These included an available pool of 27 biopsy specimens from UPSC group and 29 samples from benign control group. Any endometrial abnormalities, which morphologically qualified as EmGD as defined previously in preceding biopsies were recorded. Among all endometrial biopsies before hysterectomies, we morphologically identified a total of 10 EmGD cases; 9 (33%) of 27 were from UPSC group and 1 (3.5%) of 29 were from benign control group. All 10 morphologically diagnosed EmGD cases showed a high p53 staining score (>/=5) except 1 noncontributory from UPSC group and 1 from the benign control group with a score of 0. A high MIB-1 index score was seen in all EmGD cases, whereas low index was found in morphologically benign biopsies. The main purpose of this study is to report these retrospectively identified EmGD cases. The period from identifying EmGD to the presence of either a serous endometrial intraepithelial carcinoma or a full-blown UPSC ranged from 16 to 98 months with an average of 33 months. We conclude that occurrence of EmGD precedes the development of UPSC. The findings support our recently proposed UPSC development model, in which EmGD is likely to be a precursor lesion of UPSC. Further studies are needed to address issues in regard to molecular and cellular mechanisms, reversibility, risk of UPSC development, and clinical management of EmGD.

Entities:  

Mesh:

Year:  2007        PMID: 17197896     DOI: 10.1097/01.pgp.0000228138.56222.4e

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  13 in total

1.  Endometrial serous carcinoma (uterine papillary serous carcinoma): precancerous lesions and the theoretical promise of a preventive approach.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Am J Cancer Res       Date:  2012-04-21       Impact factor: 6.166

2.  A clinical and pathologic comparison between stage-matched endometrial intraepithelial carcinoma and uterine serous carcinoma: is there a difference?

Authors:  June Y Hou; Thomas C McAndrew; Gary L Goldberg; Kathleen Whitney; Shohreh Shahabi
Journal:  Reprod Sci       Date:  2013-09-10       Impact factor: 3.060

3.  Nrf2 expression in endometrial serous carcinomas and its precancers.

Authors:  Ning Chen; Xiaofang Yi; Nisreen Abushahin; Shujie Pang; Donna Zhang; Beihua Kong; Wenxin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2010-12-24

4.  Insights into endometrial serous carcinogenesis and progression.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2009-01-10

Review 5.  [Precursor lesions of endometrial carcinoma].

Authors:  S F Lax
Journal:  Pathologe       Date:  2019-02       Impact factor: 1.011

6.  The genomics and genetics of endometrial cancer.

Authors:  Andrea J O'Hara; Daphne W Bell
Journal:  Adv Genomics Genet       Date:  2012-03

7.  [p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumor aggressiveness in humans].

Authors:  P J Wild
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

Review 8.  Uterine papillary serous carcinoma: state of the state.

Authors:  R Wendel Naumann
Journal:  Curr Oncol Rep       Date:  2008-11       Impact factor: 5.075

9.  Molecular identification of "latent precancers" for endometrial serous carcinoma in benign-appearing endometrium.

Authors:  Xi Zhang; Sharon X Liang; Lin Jia; Ning Chen; Oluwole Fadare; Peter E Schwartz; Beihua Kong; Wenxin Zheng
Journal:  Am J Pathol       Date:  2009-05-12       Impact factor: 4.307

10.  p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans.

Authors:  Peter J Wild; Kristian Ikenberg; Thomas J Fuchs; Markus Rechsteiner; Strahil Georgiev; Niklaus Fankhauser; Aurelia Noske; Matthias Roessle; Rosmarie Caduff; Athanassios Dellas; Daniel Fink; Holger Moch; Wilhelm Krek; Ian J Frew
Journal:  EMBO Mol Med       Date:  2012-06-08       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.